Umeclidinium bromide


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Chronic obstructive pulmonary disease
Adult: Maintenance treatment: As dry powder inhaler: 1 inhalation once daily. Max: 1 inhalation once daily.
Thận trọng
Patient with severe CV disorders (especially cardiac arrhythmias); urinary retention, prostatic hyperplasia, bladder-neck obstruction; narrow-angle glaucoma. Not indicated for the rescue or initial treatment of acute episodes of bronchospasm or acutely deteriorating COPD. Not recommended in patients with asthma. Severe hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Significant: CV effects (e.g. cardiac arrhythmia, atrial fibrillation, tachycardia), hypersensitivity reactions (e.g. anaphylaxis, angioedema, pruritus, rash, urticaria); increased intraocular pressure, exacerbated urinary retention.
Eye disorders: Blurred vision. Rarely, eye pain.
Gastrointestinal disorders: Constipation, upper abdominal pain, toothache, dysgeusia, dry mouth.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Headache.
Renal and urinary disorders: UTI, dysuria.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, upper respiratory tract infection, sinusitis, cough, pharyngitis.
Potentially Fatal: Paradoxical bronchospasm.
Inhalation/Respiratory: C
Monitoring Parameters
Monitor FEV1, peak flow, and other pulmonary function test prior to and periodically during treatment. Assess for signs and symptoms of urinary retention, glaucoma, and hypersensitivity reactions.
Quá liều
Symptoms: Visual accommodation disturbances, dry mouth, and tachycardia. Management: Symptomatic and supportive treatment. Discontinue therapy and appropriately monitor patient as necessary.
Tương tác
Additive effect with other anticholinergic drugs.
Tác dụng
Description: Umeclidinium bromide is a long-acting quaternary ammonium antimuscarinic or anticholinergic agent. It competitively and reversibly inhibits the binding of acetylcholine at type 3 muscarinic (M3) receptors in the bronchial smooth muscles, thereby causing bronchodilation.
Pharmacokinetics:
Absorption: Rapidly absorbed from the lungs. Absolute bioavailability: Approx 13%. Time to peak plasma concentration: 5-15 minutes.
Distribution: Volume of distribution: 86 L (IV). Plasma protein binding: Approx 89%.
Metabolism: Metabolised in the liver mainly by CYP2D6 via oxidative (hydroxylation and O-dealkylation), followed by conjugation (glucuronidation) into a range of metabolites. It is a substrate for P-glycoprotein (P-gp) transporter.
Excretion: Mainly via faeces (approx 58%); urine (approx 22%). Elimination half-life: Approx 11-19 hours.
Đặc tính

Chemical Structure Image
Umeclidinium bromide

Source: National Center for Biotechnology Information. PubChem Database. Umeclidinium bromide, CID=11519069, https://pubchem.ncbi.nlm.nih.gov/compound/11519069#section=Structures (accessed on June 26, 2020)

Bảo quản
Store between 15-30°C. Protect from moisture, heat or sunlight.
Phân loại ATC
R03BB07 - umeclidinium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.
References
Anon. Umeclidinium. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/06/2020.

Buckingham R (ed). Umeclidinium Bromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/06/2020.

GlaxoSmithKline NZ Limited. Incruse Ellipta 62.5 micrograms, Powder for Inhalation data sheet 11 April 2017. Medsafe. http://www.medsafe.govt.nz/. Accessed 02/06/2020.

Incruse Ellipta 55 micrograms Inhalation Powder, Pre-dispensed (GlaxoSmithKline [Ireland] Limited). European Medicines Agency [online]. Accessed 17/06/2020.

Incruse Ellipta Aerosol Powder (GlaxoSmithKline LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/06/2020.

Joint Formulary Committee. Umeclidinium. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/06/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Umeclidinium bromide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in